MA28233A1 - Derives d'acylaminothiazole, leur preparation et leur application en therapeutique - Google Patents

Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Info

Publication number
MA28233A1
MA28233A1 MA29119A MA29119A MA28233A1 MA 28233 A1 MA28233 A1 MA 28233A1 MA 29119 A MA29119 A MA 29119A MA 29119 A MA29119 A MA 29119A MA 28233 A1 MA28233 A1 MA 28233A1
Authority
MA
Morocco
Prior art keywords
group
optionally substituted
alkyl
alkoxy
hydroxy
Prior art date
Application number
MA29119A
Other languages
English (en)
Inventor
Sylvie Baltzer
Dorsselaer Viviane Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0400387A external-priority patent/FR2865206B1/fr
Priority claimed from FR0408115A external-priority patent/FR2873370B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA28233A1 publication Critical patent/MA28233A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Composé répondant à la formule générale (I) dans laquelle Ri représente soit un C1-6 alkyle éventuellement substitué, soit un C3.7 cycloalkyle, un thiophène, un benzothiophène, un pyridinyle, un furanyle ou un phényle éventuellement substitué ; R2 et R¿2 représentent indépendamment l'un de l'autre un atome d'hydrogène, un atome d'halogène, un hydroxy, un C1.3 alcoxy, un C1.3 alkyle, un C3-7 cycloalkyle, un groupe O-C(O)-C1-6 alkyle, ou R2 et R'2 forment ensemble un groupe oxo ; R3 représente un atome d'hydrogène, un C1-6 alkyle éventuellement substitué par un hydroxy, un C1-6, cycloalkyle ou un C1.3 alcoxy ; l'un ou l'autre de R4 ou R5 représente un groupe (Z) et l'un ou l'autre de Rj ou R5 représente un groupe -C(X)R6 ; G représente une liaison simple ou un groupe -CH2- ; Y représente une liaison simple, un atome d'oxygène, de soufre, un groupe CM alkylène éventuellement substitué ou -N(W)- ; A et B représentent, indépendamment l'un de l'autre, un atome d'hydrogène, d'halogène, un groupe hydroxy, C1.3 alkyle, Ci. 3 alcoxy, trifluorométhyle, trifluorométhoxy ou -O-CHF2 ; X représente O ou S ; Rf, représente un groupe C|.6 alcoxy éventuellement substitué, hydroxy ou -NR?RH ; R7 et R,s représentent. indépendamment l'un de l'autre : soit un atome d'hydrogène, soit un groupe Cu, alkyle éventuellement substitué, soit un groupe C3.7 cycloalkyle éventuellement substitué. Ci-fi alcoxy ou phényle éventuellement substitué ; ou R7 et Rg, avec l'atome d'azote qui les porte, forment un cycle aziridine, azétidine, pyrrolidine, pipéridine, morpholine ou benzopipéridine ; à l'état de base, de sel d'addition à un acide ou d'hydrate. Application en thérapeutique.
MA29119A 2004-01-16 2006-06-19 Derives d'acylaminothiazole, leur preparation et leur application en therapeutique MA28233A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400387A FR2865206B1 (fr) 2004-01-16 2004-01-16 Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR0408115A FR2873370B1 (fr) 2004-07-22 2004-07-22 Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
MA28233A1 true MA28233A1 (fr) 2006-10-02

Family

ID=34828645

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29119A MA28233A1 (fr) 2004-01-16 2006-06-19 Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Country Status (14)

Country Link
US (1) US7582664B2 (fr)
EP (1) EP1709041A1 (fr)
JP (1) JP2007517840A (fr)
AR (1) AR047387A1 (fr)
AU (1) AU2005209442B2 (fr)
BR (1) BRPI0506880A (fr)
CA (1) CA2551142A1 (fr)
IL (1) IL176701A (fr)
MA (1) MA28233A1 (fr)
NO (1) NO20063675L (fr)
NZ (1) NZ548531A (fr)
RU (1) RU2401262C2 (fr)
TW (1) TWI340642B (fr)
WO (1) WO2005073226A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084391A2 (fr) * 2006-01-18 2007-07-26 Amgen Inc. Composes thiazole et procedes d'utilisation
EP2173728A2 (fr) 2007-07-17 2010-04-14 Amgen Inc. Modulateurs hétérocycliques de pkb
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401034D0 (en) * 1994-01-20 1994-03-16 British Bio Technology Metalloproteinase inhibitors
JP2001504498A (ja) * 1996-11-22 2001-04-03 エラン・ファーマシューティカルズ・インコーポレイテッド Ｎ―（アリール／ヘテロアリール／アルキルアセチル）アミノ酸アミドおよびその医薬組成物、並びに該化合物を用いたβ―アミロイドペプチドの放出および／またはその合成を阻害する方法
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP2006504796A (ja) * 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性性障害を処置するためのチアゾール化合物
PT1709018E (pt) * 2004-01-16 2011-10-24 Sanofi Sa Derivados de acilaminotiazole e sua aplicação como inibidores

Also Published As

Publication number Publication date
US20060293365A1 (en) 2006-12-28
TW200533345A (en) 2005-10-16
BRPI0506880A (pt) 2007-06-26
WO2005073226A1 (fr) 2005-08-11
IL176701A0 (en) 2006-10-31
RU2006129642A (ru) 2008-02-27
CA2551142A1 (fr) 2005-08-11
RU2401262C2 (ru) 2010-10-10
NZ548531A (en) 2010-01-29
AU2005209442B2 (en) 2011-03-31
AR047387A1 (es) 2006-01-18
JP2007517840A (ja) 2007-07-05
EP1709041A1 (fr) 2006-10-11
TWI340642B (en) 2011-04-21
US7582664B2 (en) 2009-09-01
IL176701A (en) 2012-01-31
NO20063675L (no) 2006-10-16
AU2005209442A1 (en) 2005-08-11
HK1104542A1 (en) 2008-01-18

Similar Documents

Publication Publication Date Title
MA28097A1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique
RU2214400C2 (ru) Производные 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способы их получения, фармацевтическая композиция на их основе и промежуточные вещества
DE60324155D1 (de) Indol-3-carbinol metaboliten als chemotherapeutische und chemopräventive wirkstoffen
TNSN04208A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique
MA28098A1 (fr) Derives de n-[phenyl ( pyrrolidin-2-yl ) methyl] benzamide et n-[(azepan-2-yl) phenylmethyl] benzamide, leur preparation et leur application en therapeutique
RU2005110061A (ru) Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло(2,2,1)гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина
MA29698B1 (fr) Dérivés de n-(hétéroaryl)-1-hétéroarylalkyl-1h-indole-2-carboxamides, leur préparation et leur application en thérapeutique.
AR045255A1 (es) Derivados de 1,2 benzodiazol
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
AR036939A1 (es) Antagonistas de la hormona de concentracion de melanina (mch) composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o en combinacion, para la elaboracion de un medicamento para el tratamiento de obesidad
RU2006105717A (ru) Производные пиперазина и их применение в качестве терапевтических агентов
TNSN07041A1 (fr) Derives de n-(1 h-indolyl)-i h-indole-2-carboxamides, leur preparation et leur application en therapeutique
EA200600892A1 (ru) Новые хинолиновые производные
EA200870384A1 (ru) 3,7-диамино-10h-фенотиазиновые соли и их применение
PE20040644A1 (es) Nuevos derivados de quinuclidina-amina
CA2656716C (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
MA32088B1 (fr) Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique
MA33893B1 (fr) Derives de diphenyl-pyrazolopyridines,leur preparation et leur appalication en therapeutique
MA28422B1 (fr) Derives de n- (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1
EP1840125A3 (fr) Intermédiaires pour la production de dioxane-2-alkylcarbamates
TNSN07253A1 (fr) Derives de n- (heteroaryl) -1h-indole-2-carboxamides et leur utilisation comme ligands du recepteur vanilloide trpv1
RU2004121688A (ru) 7-аминобензотиазольные производные в качестве лигандов аденозинового рецептора
RU2004111601A (ru) Пиперидиновые производные и их применение в качестве модуляторов активности р ецепторов хемокина (в частности ccr5)
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
CO5690599A2 (es) Derivados de 3-(4-aminofenil) tienopirimid-4-ona como antagonistas mch r1 para el tratamiento de obesidad, diabetes, depresion y ansiedad